We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Ranbaxy’s GMP Issues Lead Daiichi to Tighten Grip on Management
Ranbaxy’s GMP Issues Lead Daiichi to Tighten Grip on Management
June 2, 2009
Ranbaxy’s new parent company, Daiichi Sankyo, will tighten its grip on the generic-drug maker to help resolve GMP compliance issues that led the FDA to invoke its application integrity policy (AIP) for Ranbaxy.